Mr. Speaker, it sometimes occurs that there are new drugs under consideration that might help those who are dying or are very seriously ill. If the conclusion is reached that the benefits of those drugs outweigh their risks, where the company that is proposing it agrees to continue studying it and we monitor the performance of that drug, then is the member saying that she would deny access to that drug to those who might otherwise die? Would she turn them down when these drugs might improve their condition or indeed even save their lives?
That is at the basis of this policy.